• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

BNT162b2 mRNA vaccine for COVID-19 prevention [Classics Series]

byDeepti Shroff Karhade
July 12, 2022
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This clinical trial determined the efficacy of the BNT162b2 mRNA vaccine at preventing coronavirus disease 2019 (COVID-19) infection (94.6%) based on comparison to a placebo control group.

2. Rates of serious adverse events did not differ significantly between the BNT162b2 vaccine and control groups.

Original Date of Publication: December 2020

Study Rundown: This clinical efficacy trial compared COVID-19 infection rates of patients receiving the BNT162b2 mRNA vaccine and of those receiving a placebo control. Participants in the streatment group had significantly reduced COVID-19 infection rates when compared to those receiving placebo controls. Vaccine efficacy did not vary based on demographic subgroup analysis. Overall adverse events were higher in the BNT162b2 group, but serious adverse event rates did not differ significantly between groups. The present study has limited generalizability to certain higher risk populations, including children,pregnant individuals and immunocompromised individuals as they were not studied. These groups are commonly excluded from initial safety and efficacy trials to minimize confounding risk factors. In summary, this study demonstrates that the BNT162b2 mRNA vaccine provided a high-degree of COVID-19 protection with limited risk of serious adverse events.

Click to read the study in NEJM

RELATED REPORTS

Poor communication closely associated with patient safety incidents

#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary

The 2 Minute Medicine Podcast Episode 27

In-Depth [randomized control trial]: This efficacy and safety trial randomized COVID-19 naïve participants to receive two doses of either the BNT162b2 mRNA vaccine (n = 21 720) or a placebo control (n = 21 728). Injections were given intramuscularly 21 days apart in both groups to adults aged 16 years or older. BNT162b2 mRNA vaccine efficacy was measured using rates of COVID-19 infection at least one week following second dose and was found to be 95% (95%CI 90.3-97.6). With only one dose, vaccine efficacy was 52% (95%CI 29.5-68.4). The safety profile of the BNT162b2 vaccine was measured at two-month follow-up. A higher rate of adverse events was reported in the intervention group (27%) as compared to the control group (12%). Serious adverse events did not differ significantly between groups, although safety monitoring will continue for two years after baseline.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–15.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adverse eventsbnt162b2CoronavirusmRNA vaccine
Previous Post

ARIC study finds obstructive and restrictive spirometry results to be associated with heart failure

Next Post

Inappropriate sleep duration may influence the economic burden of health care

RelatedReports

Shared decision-making may be limited in PICU end-of-life discussions
Public Health

Poor communication closely associated with patient safety incidents

April 15, 2025
#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary
StudyGraphics

#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary

August 20, 2024
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 27

November 2, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Next Post
Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain

Inappropriate sleep duration may influence the economic burden of health care

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]

Routine primary thromboprophylaxis with enoxaparin safe in children with COVID-19 or MIS-C

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.